In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Dimitrios C ArhontoulisMolecular Cellular Biology and Pathobiology, Medical University of South Carolina, USA.ORCID 0000-0002-7959-7692 Lauren N RandolphDepartment of Biomedical Engineering, The Pennsylvania State University, USA.
Mei LiDepartment of Cardiology, Medical University of South Carolina, USA.
Charles M KerrMolecular Cellular Biology and Pathobiology, Medical University of South Carolina, USA.ORCID 0000-0001-8736-4795 Jordan E MorningstarDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, USA.ORCID 0000-0003-2168-9671 Martha E FloyDepartment of Chemical and Biological Engineering, University of Madison-Wisconsin, USA.ORCID 0000-0003-1992-5911 Russell A NorrisDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, USA.ORCID 0000-0001-8462-5726 Jean Marie RuddyDepartment of Surgery, Medical University of South Carolina, USA.
Sean P PalecekDepartment of Chemical and Biological Engineering, University of Madison-Wisconsin, USA.ORCID 0000-0003-4917-5584 Leonardo M R FerreiraDepartment of Pharmacology and Immunology, Medical University of South Carolina, USA.ORCID 0000-0003-2491-9866 Funding
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7MSC COBRE for Developmentally Based Cardiovascular DiseasesP30GM103342 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MARKWALD, ROGER R · 2012 to 2016
$5.5MLabel-free single-cell imaging for quality control of cardiomyocyte biomanufacturingR01HL165726 · NHLBI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI Sean P Palecek, Melissa Caroline Skala · 2023 to 2026
$2.5MNanowired hypoimmunogenic hPSC cardiac organoids for heart repairR01HL175050 · NHLBI · CLEMSON UNIVERSITY · PI XIAOJUN LIAN, Ying Mei · 2024 to 2026
$2.0MNanowired human cardiac spheroids for heart repairR01HL133308 · NHLBI · CLEMSON UNIVERSITY · PI MEI, YING · 2017 to 2020
$1.5MNanowired humam cardiac organoid derived exosomes for heart repairR01HL168255 · NHLBI · CLEMSON UNIVERSITY · PI Ying Mei · 2023 to 2026
$1.5MSilicon nanowire engineered human isogenic cardiac organoids for heart repairR01HL173532 · NHLBI · CLEMSON UNIVERSITY · PI Ying Mei · 2025 to 2026
$1.1MNanowired human isogenic cardiac organoids to treat acute myocardial ischemia/reperfusion injuriesU01HL169361 · NHLBI · CLEMSON UNIVERSITY · PI MEI, YING · 2023 to 2024
$746kStem cell immunoengineering for universal cardiac therapy via CRISPR-Cas9R21EB026035 · NIBIB · PENNSYLVANIA STATE UNIVERSITY, THE · PI LIAN, XIAOJUN · 2018 to 2020
$567kModRNA-based Direct Programming of Universal Donor hiPSCs into Immune Evasive Beta CellsR56DK133147 · NIDDK · PENNSYLVANIA STATE UNIVERSITY, THE · PI LIAN, XIAOJUN · 2023 to 2024
$465kHuman organoid model for COVID-19 myocarditisR21HL167211 · NHLBI · CLEMSON UNIVERSITY · PI MEI, YING · 2023 to 2024
$411kThe Use of Human Cardiac Organoids to Model COVID-19 Cytokine Storm Induced Cardiac InjuryF30HL160055 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ARHONTOULIS, DIMITRIOS CHRISOVALANTOU · 2022 to 2024
$151kNCI NIH HHS P30 CA138313NHLBI NIH HHS F30 HL160055NHLBI NIH HHS F31 HL154665NHLBI NIH HHS F31 HL156541NHLBI NIH HHS R01 HL133308NHLBI NIH HHS R01 HL165726NHLBI NIH HHS R01 HL168255NHLBI NIH HHS R01 HL173532NHLBI NIH HHS R01 HL175050NHLBI NIH HHS R21 HL167211NHLBI NIH HHS U01 HL169361NIBIB NIH HHS R21 EB026035NIDDK NIH HHS R56 DK133147NIGMS NIH HHS P30 GM103342
6 · The paper itselfAbstract
Human pluripotent stem cell (hPSC)-derived cardiac therapies hold great promise for heart regeneration but face major translational barriers due to allogeneic immune rejection. Here, we engineered hypoimmunogenic hPSCs using a two-step CRISPR-Cas9 strategy: (1) B2M knockout, eliminating HLA class I surface expression, and (2) knock-in of HLA-E or HLA-G trimer constructs in the AAVS1 safe harbor locus to confer robust immune evasion. Hypoimmunogenic hPSCs maintained pluripotency, efficiently differentiated into cardiac cell types that resisted both T and NK cell-mediated cytotoxicity
Identifiers
PMID40291708
PMCPMC12027337
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390